Pfizer Begin Period Cash Flow vs Free Cash Flow Analysis

PFE Stock

USD 25.57 0.53 2.03%

Pfizer financial indicator trend analysis is much more than just breaking down Pfizer Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pfizer Inc is a good investment. Please check the relationship between Pfizer Begin Period Cash Flow and its Free Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

Begin Period Cash Flow vs Free Cash Flow

Begin Period Cash Flow vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pfizer Inc Begin Period Cash Flow account and Free Cash Flow. At this time, the significance of the direction appears to have very week relationship.

The correlation between Pfizer's Begin Period Cash Flow and Free Cash Flow is 0.27. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Pfizer Inc, assuming nothing else is changed. The correlation between historical values of Pfizer's Begin Period Cash Flow and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Pfizer Inc are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Begin Period Cash Flow i.e., Pfizer's Begin Period Cash Flow and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.27

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from Pfizer's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pfizer Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

At present, Pfizer's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 87.3 B, whereas Tax Provision is projected to grow to (1.1 B).

	2021	2022	2023	2024 (projected)
Gross Profit	50.5B	66.0B	28.8B	30.4B
Total Revenue	81.3B	100.3B	58.5B	39.5B

Gross Profit Total Revenue

Pfizer fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Property Plant Equipment	Accounts Payable	Common Stock Total Equity
Total Assets		0.85	0.7	0.88	0.77	0.84	0.82	0.77	0.25	0.97	0.56	0.44	0.54	0.2	0.93	0.73	0.6	-0.12	0.98	0.71	0.64	0.35	0.87	0.84	0.87	0.91
Short Long Term Debt Total	0.85		0.61	0.86	0.41	0.61	0.99	0.77	0.06	0.93	0.37	0.0	0.18	0.14	0.84	0.54	0.8	-0.36	0.91	0.71	0.21	0.5	0.84	0.61	0.81	0.71
Other Current Liab	0.7	0.61		0.87	0.52	0.58	0.61	0.79	-0.07	0.7	0.84	0.16	0.34	0.34	0.44	0.59	0.72	-0.44	0.64	0.92	0.36	-0.12	0.49	0.58	0.89	0.54
Total Current Liabilities	0.88	0.86	0.87		0.59	0.73	0.85	0.9	-0.01	0.91	0.68	0.12	0.37	0.21	0.71	0.73	0.74	-0.47	0.88	0.84	0.37	0.35	0.72	0.73	0.96	0.78
Total Stockholder Equity	0.77	0.41	0.52	0.59		0.92	0.37	0.55	0.3	0.66	0.67	0.64	0.72	0.25	0.66	0.87	0.2	0.08	0.68	0.46	0.86	0.21	0.55	0.92	0.62	0.81
Property Plant And Equipment Net	0.84	0.61	0.58	0.73	0.92		0.58	0.63	0.24	0.79	0.62	0.41	0.72	0.24	0.76	0.95	0.31	-0.05	0.8	0.57	0.71	0.37	0.67	1.0	0.72	0.87
Net Debt	0.82	0.99	0.61	0.85	0.37	0.58		0.79	-0.06	0.91	0.36	-0.07	0.11	0.11	0.79	0.52	0.83	-0.44	0.88	0.71	0.15	0.51	0.81	0.58	0.8	0.68
Retained Earnings	0.77	0.77	0.79	0.9	0.55	0.63	0.79		-0.24	0.82	0.68	0.05	0.13	0.1	0.6	0.7	0.79	-0.71	0.76	0.84	0.28	0.28	0.54	0.63	0.92	0.78
Cash	0.25	0.06	-0.07	-0.01	0.3	0.24	-0.06	-0.24		0.14	-0.05	0.5	0.58	0.21	0.35	0.09	-0.27	0.65	0.23	-0.1	0.47	0.06	0.26	0.24	-0.02	0.16
Non Current Assets Total	0.97	0.93	0.7	0.91	0.66	0.79	0.91	0.82	0.14		0.56	0.22	0.41	0.14	0.91	0.7	0.71	-0.26	0.98	0.76	0.44	0.42	0.9	0.79	0.9	0.86
Non Currrent Assets Other	0.56	0.37	0.84	0.68	0.67	0.62	0.36	0.68	-0.05	0.56		0.17	0.39	0.34	0.28	0.64	0.52	-0.34	0.46	0.76	0.37	-0.12	0.36	0.62	0.76	0.45
Cash And Short Term Investments	0.44	0.0	0.16	0.12	0.64	0.41	-0.07	0.05	0.5	0.22	0.17		0.55	0.06	0.44	0.29	-0.17	0.48	0.35	0.0	0.91	-0.13	0.21	0.41	0.13	0.48
Net Receivables	0.54	0.18	0.34	0.37	0.72	0.72	0.11	0.13	0.58	0.41	0.39	0.55		0.48	0.46	0.61	-0.22	0.46	0.46	0.24	0.73	0.05	0.41	0.72	0.35	0.52
Common Stock Shares Outstanding	0.2	0.14	0.34	0.21	0.25	0.24	0.11	0.1	0.21	0.14	0.34	0.06	0.48		0.04	0.19	0.1	0.13	0.11	0.32	0.24	-0.25	0.08	0.24	0.2	0.07
Non Current Liabilities Total	0.93	0.84	0.44	0.71	0.66	0.76	0.79	0.6	0.35	0.91	0.28	0.44	0.46	0.04		0.61	0.49	0.03	0.96	0.51	0.6	0.47	0.89	0.76	0.68	0.87
Inventory	0.73	0.54	0.59	0.73	0.87	0.95	0.52	0.7	0.09	0.7	0.64	0.29	0.61	0.19	0.61		0.31	-0.26	0.7	0.58	0.61	0.39	0.49	0.95	0.7	0.83
Other Current Assets	0.6	0.8	0.72	0.74	0.2	0.31	0.83	0.79	-0.27	0.71	0.52	-0.17	-0.22	0.1	0.49	0.31		-0.64	0.62	0.82	-0.03	0.12	0.56	0.31	0.76	0.41
Other Stockholder Equity	-0.12	-0.36	-0.44	-0.47	0.08	-0.05	-0.44	-0.71	0.65	-0.26	-0.34	0.48	0.46	0.13	0.03	-0.26	-0.64		-0.17	-0.53	0.34	-0.17	0.05	-0.05	-0.48	-0.21
Total Liab	0.98	0.91	0.64	0.88	0.68	0.8	0.88	0.76	0.23	0.98	0.46	0.35	0.46	0.11	0.96	0.7	0.62	-0.17		0.68	0.55	0.46	0.89	0.8	0.84	0.9
Property Plant And Equipment Gross	0.71	0.71	0.92	0.84	0.46	0.57	0.71	0.84	-0.1	0.76	0.76	0.0	0.24	0.32	0.51	0.58	0.82	-0.53	0.68		0.22	-0.1	0.53	0.57	0.89	0.57
Total Current Assets	0.64	0.21	0.36	0.37	0.86	0.71	0.15	0.28	0.47	0.44	0.37	0.91	0.73	0.24	0.6	0.61	-0.03	0.34	0.55	0.22		0.03	0.38	0.71	0.38	0.7
Short Term Debt	0.35	0.5	-0.12	0.35	0.21	0.37	0.51	0.28	0.06	0.42	-0.12	-0.13	0.05	-0.25	0.47	0.39	0.12	-0.17	0.46	-0.1	0.03		0.43	0.37	0.2	0.43
Intangible Assets	0.87	0.84	0.49	0.72	0.55	0.67	0.81	0.54	0.26	0.9	0.36	0.21	0.41	0.08	0.89	0.49	0.56	0.05	0.89	0.53	0.38	0.43		0.67	0.73	0.68
Property Plant Equipment	0.84	0.61	0.58	0.73	0.92	1.0	0.58	0.63	0.24	0.79	0.62	0.41	0.72	0.24	0.76	0.95	0.31	-0.05	0.8	0.57	0.71	0.37	0.67		0.72	0.87
Accounts Payable	0.87	0.81	0.89	0.96	0.62	0.72	0.8	0.92	-0.02	0.9	0.76	0.13	0.35	0.2	0.68	0.7	0.76	-0.48	0.84	0.89	0.38	0.2	0.73	0.72		0.76
Common Stock Total Equity	0.91	0.71	0.54	0.78	0.81	0.87	0.68	0.78	0.16	0.86	0.45	0.48	0.52	0.07	0.87	0.83	0.41	-0.21	0.9	0.57	0.7	0.43	0.68	0.87	0.76

Click cells to compare fundamentals

Pfizer Account Relationship Matchups

Pfizer fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	167.5B	154.2B	181.5B	197.2B	226.5B	237.8B
Short Long Term Debt Total	52.1B	39.8B	38.4B	35.8B	75.0B	78.8B
Total Current Liabilities	37.3B	25.9B	42.7B	42.1B	47.8B	50.2B
Total Stockholder Equity	63.1B	63.2B	77.2B	95.7B	89.0B	46.9B
Property Plant And Equipment Net	14.0B	13.9B	14.9B	16.3B	18.9B	11.3B
Net Debt	50.8B	36.5B	35.1B	34.5B	72.2B	75.8B
Retained Earnings	97.7B	96.8B	103.4B	125.7B	118.4B	124.3B
Cash	1.3B	1.8B	1.9B	416M	2.9B	2.0B
Non Current Assets Total	134.7B	119.2B	121.8B	145.9B	183.2B	192.3B
Non Currrent Assets Other	4.5B	4.6B	7.7B	13.2B	9.1B	5.3B
Cash And Short Term Investments	9.8B	12.2B	31.1B	22.7B	12.7B	14.9B
Net Receivables	12.1B	11.2B	15.7B	14.5B	11.2B	8.7B
Common Stock Shares Outstanding	5.7B	5.6B	5.7B	5.7B	5.7B	5.7B
Liabilities And Stockholders Equity	167.5B	154.2B	181.5B	197.2B	226.5B	237.8B
Non Current Liabilities Total	66.7B	64.8B	61.3B	59.2B	89.4B	93.9B
Inventory	8.3B	8.0B	9.1B	9.0B	10.2B	5.2B
Other Current Assets	2.6B	3.4B	3.8B	5.0B	9.3B	9.7B
Other Stockholder Equity	(23.4B)	(22.3B)	(20.8B)	(22.2B)	(21.9B)	(20.8B)
Total Liab	104.0B	90.8B	104.0B	101.3B	137.2B	144.1B
Property Plant And Equipment Gross	14.0B	28.4B	30.0B	31.4B	35.0B	36.7B
Total Current Assets	32.8B	35.1B	59.7B	51.3B	43.3B	32.2B
Short Term Debt	16.2B	2.7B	2.2B	2.9B	10.9B	5.7B
Intangible Assets	35.4B	28.5B	25.1B	43.4B	64.9B	68.1B
Property Plant Equipment	14.0B	13.9B	14.9B	16.3B	18.9B	11.3B
Accounts Payable	4.2B	4.3B	5.6B	6.8B	6.7B	7.0B
Accumulated Other Comprehensive Income	(11.6B)	(11.7B)	(5.9B)	(8.3B)	(8.0B)	(7.6B)
Common Stock Total Equity	468M	470M	473M	476M	478M	474.0M
Short Term Investments	8.5B	10.4B	29.1B	22.3B	9.8B	9.3B
Capital Stock	468M	470M	473M	476M	478M	474.0M
Common Stock	468M	470M	473M	476M	478M	474.0M
Other Liab	29.7B	26.6B	22.6B	23.3B	26.9B	22.1B
Other Assets	4.2B	4.3B	5.6B	6.8B	6.7B	5.0B
Long Term Debt	36.0B	37.1B	36.2B	32.9B	60.5B	63.5B
Good Will	58.7B	49.6B	49.2B	51.4B	67.8B	40.7B
Treasury Stock	(110.8B)	(111.0B)	(111.4B)	(114.0B)	(114.5B)	(108.8B)
Current Deferred Revenue	5.8B	6.3B	3.1B	2.5B	2.7B	3.9B
Net Tangible Assets	(30.9B)	63.2B	77.2B	95.7B	89.0B	93.5B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:

How To Invest In Pfizer

Details

Is Pfizer Stock a good investment?

Details

What is Pfizer's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.98)

Dividend Share

1.67

Earnings Share

0.75

Revenue Per Share

10.493

Quarterly Revenue Growth

0.312

The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pfizer Begin Period Cash Flow vs Free Cash Flow Analysis

Begin Period Cash Flow vs Free Cash Flow

Begin Period Cash Flow vs Free Cash Flow Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Free Cash Flow

Pfizer fundamental ratios Correlations

Pfizer Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pfizer fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant Equipment	+ 1.0	Property Plant And Equipment Net
Net Debt	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.98	Total Assets
Total Liab	+ 0.98	Non Current Assets Total
Non Current Assets Total	+ 0.97	Total Assets
Accounts Payable	+ 0.96	Total Current Liabilities

Other Stockholder Equity	- 0.71	Retained Earnings
Other Stockholder Equity	- 0.64	Other Current Assets
Property Plant And Equipment Gross	- 0.53	Other Stockholder Equity
Accounts Payable	- 0.48	Other Stockholder Equity
Other Stockholder Equity	- 0.47	Total Current Liabilities
Other Stockholder Equity	- 0.44	Net Debt